Want to see XNCR full AI Analyst Report?
XNCR Stock Chart & Stats
$13.06
-$0.21(-0.88%)
At close: 4:00 PM EST
$13.06
-$0.21(-0.88%)
Day’s Range― - ―
52-Week Range$6.92 - $18.69
Previous CloseN/A
Volume126.93K
Average Volume (3M)765.42K
Market Cap
$937.15M
Enterprise Value$1.11B
Total Cash (Recent Filing)$444.95M
Total Debt (Recent Filing)$175.16M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Aug 05, 2026EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.29
Shares Outstanding74,141,594
10 Day Avg. Volume876,689
30 Day Avg. Volume765,420
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.79
Price to Sales (P/S)9.05
P/FCF Ratio-8.22
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue11.39
Enterprise Value/Gross Profit31.50
Enterprise Value/Ebitda-8.42
Forecast
1Y Price Target
$24.30Price Target Upside86.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.88
Revenue Forecast (FY)$77.44M
Bulls Say, Bears Say
Bulls Say
Proprietary Antibody Engineering PlatformXencor’s XmAb and Xtend Fc platforms provide durable product differentiation across oncology and immunology programs. A reusable engineering toolkit enables multiple candidates, supports partner licensing, and raises technical switching costs for competitors, underpinning sustained pipeline and collaboration value.
Manageable Leverage On Balance SheetLow debt relative to equity gives Xencor financial flexibility to fund R&D and clinical programs without immediate refinancing pressure. This balance-sheet headroom reduces short-term liquidity risk and supports sustaining long-duration development efforts central to biotech value creation.
Board/shareholder Support For Talent IncentivesApproval to expand the equity incentive plan signals governance alignment and provides a tool to retain scientific and executive talent. Strong retention programs are critical in clinical-stage biotechs to maintain institutional knowledge and advance complex development programs over multi-year horizons.
Bears Say
High Cash Burn And Negative Free Cash FlowSustained, large negative operating and free cash flows indicate material cash burn from R&D and operations. Over months this elevates funding risk, likely necessitating financing or partner deals that can dilute shareholders or alter R&D pacing if clinical progress or milestone payments don't materialize.
Declining Revenue And Large Net LossesA meaningful drop in trailing revenue combined with very large net losses shows current operations are not self-sustaining. Persistent negative margins constrain reinvestment capacity and increase dependence on external funding or milestone timing to sustain development and commercialization plans.
Binary Clinical-stage Program RiskWith core value tied to early- to mid-stage clinical readouts, Xencor faces binary outcome risk: trial setbacks can materially delay or negate anticipated milestones and partner payments. This structural exposure makes cash runway and milestone diversification critical long-term considerations.
Xencor News
XNCR FAQ
What was Xencor Inc.’s price range in the past 12 months?
Xencor Inc. lowest stock price was $6.92 and its highest was $18.69 in the past 12 months.
What is Xencor Inc.’s market cap?
Xencor Inc.’s market cap is $937.15M.
When is Xencor Inc.’s upcoming earnings report date?
Xencor Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 31 days.
How were Xencor Inc.’s earnings last quarter?
Xencor Inc. released its earnings results on May 06, 2026. The company reported -$1.71 earnings per share for the quarter, missing the consensus estimate of -$0.829 by -$0.881.
Is Xencor Inc. overvalued?
According to Wall Street analysts Xencor Inc.’s price is currently Undervalued.
Does Xencor Inc. pay dividends?
Xencor Inc. does not currently pay dividends.
What is Xencor Inc.’s EPS estimate?
Xencor Inc.’s EPS estimate is -0.8.
How many shares outstanding does Xencor Inc. have?
Xencor Inc. has 74,141,594 shares outstanding.
What happened to Xencor Inc.’s price movement after its last earnings report?
Xencor Inc. reported an EPS of -$1.71 in its last earnings report, missing expectations of -$0.829. Following the earnings report the stock price went down -5.38%.
Which hedge fund is a major shareholder of Xencor Inc.?
Currently, no hedge funds are holding shares in XNCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xencor Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.30 (86.06% Upside)
$24.30 (86.06% Upside)
Blogger Sentiment
Bullish
XNCR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $43.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.7%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.72%
12-Months-Change
Fundamentals
Return on Equity
-28.77%
Trailing 12-Months
Asset Growth
-18.55%
Trailing 12-Months
Company Description
Xencor Inc.
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
XNCR Stock 12 Month Forecast
Average Price Target
$24.30
▲(86.06% Upside)
Technical Analysis
Dianthus Therapeutics
―
Autolus Therapeutics
―
Stoke Therapeutics
―
Relay Therapeutics
―
Maravai Lifesciences Holdings
―
Ownership Overview
1.39% Insiders
29.38% Mutual Funds
0.19% Other Institutional Investors
42.34% Public Companies and
Individual Investors